PharVision Advisers LLC Takes $259,000 Position in Privia Health Group, Inc. (NASDAQ:PRVA)

PharVision Advisers LLC purchased a new position in shares of Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 13,231 shares of the company's stock, valued at approximately $259,000.

A number of other large investors have also recently bought and sold shares of PRVA. First Horizon Advisors Inc. raised its holdings in shares of Privia Health Group by 53.8% in the fourth quarter. First Horizon Advisors Inc. now owns 1,807 shares of the company's stock valued at $35,000 after buying an additional 632 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in Privia Health Group by 7,833.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,380 shares of the company's stock valued at $47,000 after acquiring an additional 2,350 shares during the period. Quadrant Capital Group LLC increased its position in Privia Health Group by 11.8% in the 4th quarter. Quadrant Capital Group LLC now owns 4,855 shares of the company's stock valued at $95,000 after acquiring an additional 511 shares during the period. Nisa Investment Advisors LLC raised its stake in Privia Health Group by 185.7% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,999 shares of the company's stock valued at $98,000 after acquiring an additional 3,249 shares during the last quarter. Finally, KBC Group NV lifted its position in Privia Health Group by 48.1% during the 4th quarter. KBC Group NV now owns 5,012 shares of the company's stock worth $98,000 after acquiring an additional 1,627 shares during the period. Institutional investors and hedge funds own 94.48% of the company's stock.

Insider Activity

In other news, Director Matthew Shawn Morris sold 10,309 shares of the business's stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $23.33, for a total value of $240,508.97. Following the completion of the transaction, the director now directly owns 59,792 shares of the company's stock, valued at $1,394,947.36. The trade was a 14.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Parth Mehrotra sold 15,100 shares of the company's stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $23.33, for a total value of $352,283.00. Following the completion of the sale, the chief executive officer now owns 454,281 shares in the company, valued at $10,598,375.73. This represents a 3.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 51,579 shares of company stock worth $1,226,367. Company insiders own 10.70% of the company's stock.

Analysts Set New Price Targets

PRVA has been the topic of several analyst reports. Piper Sandler lifted their target price on Privia Health Group from $25.00 to $40.00 and gave the company an "overweight" rating in a research note on Friday, February 28th. Robert W. Baird lifted their price objective on shares of Privia Health Group from $24.00 to $26.00 and gave the company an "outperform" rating in a research report on Tuesday, April 15th. Truist Financial boosted their price objective on shares of Privia Health Group from $27.00 to $28.00 and gave the company a "buy" rating in a research note on Thursday, April 10th. JMP Securities restated a "market outperform" rating and issued a $29.00 target price on shares of Privia Health Group in a research note on Monday, April 28th. Finally, Canaccord Genuity Group lifted their target price on shares of Privia Health Group from $29.00 to $30.00 and gave the company a "buy" rating in a report on Friday, February 28th. One analyst has rated the stock with a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $27.46.

Privia Health Group Stock Up 2.8%

Shares of NASDAQ PRVA traded up $0.63 during midday trading on Tuesday, hitting $23.49. The company had a trading volume of 143,218 shares, compared to its average volume of 736,599. The firm has a market capitalization of $2.86 billion, a price-to-earnings ratio of 235.25, a price-to-earnings-growth ratio of 3.47 and a beta of 0.87. Privia Health Group, Inc. has a twelve month low of $16.37 and a twelve month high of $26.09. The business has a 50-day simple moving average of $23.37 and a two-hundred day simple moving average of $22.71.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.